Modeling Opportunities in Comparative Oncology for Drug Development

Modeling opportunities in comparative oncology for drug development.

Successful development of novel cancer drugs depends on well-reasoned scientific drug discovery, rigorous preclinical development, and carefully conceived clinical trials. Failure in any of these steps contributes to poor rates of approval for new drugs to treat cancer. As technological and scientific advances have opened the door to a variety of novel approaches to cancer drug discovery and de...

Biomarkers in oncology drug development.

Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. For those drugs taken forward, biomarker measurements may also ...

Mapping the Future in Oncology Drug Development

Drug-Diagnostics Co-Development in Oncology

Developments in genomics are providing a biological basis for the heterogeneity of clinical course and response to treatment that have long been apparent to clinicians. The ability to molecularly characterize human diseases presents new opportunities to develop more effective treatments and new challenges for the design and analysis of clinical trials. In oncology, treatment of broad population...

Toward patient-centered drug development in oncology.

n engl j med 369;5 nejm.org august 1, 2013 397 this treatment?” Regrettably, this information is generally missing from U.S. drug labels and from published reports of clinical trials — the two information sources most commonly available to people trying to understand the clinical effects of cancer drugs. In 2011, 15 hematology–oncology drugs were approved by the U.S. Food and Drug Administratio...